

Efficacy of insulin targeted gene therapy for type 1 diabetes mellitus: A systematic review and meta-analysis of rodent studies

Moosa Rahimi Ghiasi¹, Hamed Mohammadi², Michael E. Symonds³, Seyed Mohammad Bagher Tabei⁴, Ahmad Reza Salehi¹, Sima Jafarpour¹, Leila Norouzi Barough¹, Elnaz Rahimi¹, Zohreh Amirkhani¹, Maryam Miraghajani^{5,3}, Rasoul Salehi^{1,6*}

¹Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

²Food Security Research Center, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

³The Early Life Research Unit, Division of Child Health, Obstetrics and Gynaecology, and Nottingham Digestive Disease Centre and Biomedical Research Centre, School of Medicine, University of Nottingham, Nottingham, UK

⁴Department of Genetics & Maternal-Fetal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

⁵Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁶Pediatric Inherited Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

ARTICLE INFO

Article type:

Review article

Article history:

Received: Apr 9, 2019

Accepted: Oct 6, 2019

Keywords:

Gene therapy

Insulin

Meta-analysis

Non-viral vector

Type 1 diabetes mellitus

Viral vector

ABSTRACT

Diabetes mellitus (DM) is a major worldwide public health challenge, for which gene therapy offers a potential therapeutic approach. To date, no systematic review or meta-analysis has been published in this area, so we examined all relevant published studies on rodents to elucidate the overall effects of gene therapy on bodyweight, intraperitoneal glucose tolerance test (IPGTT), fasting blood glucose, and insulin in animals with type 1 DM. The Cochrane Library, PubMed, Embase, ISI Web of Science, SCOPUS, and Google Scholar were systematically searched for potentially relevant studies. Mean±standard deviation (SD) was pooled using a random-effects model. After the primary search, out of 528 studies identified, 16 studies were in concordance with predefined criteria and selected for the final assessment. Of these, 12 studies used viral manipulation, and 4 employed non-viral vectors for gene delivery. The meta-analysis showed gene therapy with a viral vector decreased mean IPGTT (-12.69 mmol/l, $P<0.001$), fasting blood glucose (-13.51 mmol/l, $P<0.001$), insulin (398.28 pmol/l, $P<0.001$), and bodyweight (24.22 g, $P<0.001$), whereas non-viral vectors reduced fasting glucose (-29.95 mmol/l, $P<0.001$) and elevated insulin (114.92 pmol/l, $P<0.001$). Gene therapy has favorable effects on alleviating type 1 DM related factors in diabetic rodents.

► Please cite this article as:

Rahimi Ghiasi M, Mohammadi H, Symonds ME, Tabei SMB, Salehi AR, Jafarpour S, Norouzi Barough L, Amirkhani Z, Rahimi E, Miraghajani M, Salehi R. Efficacy of insulin targeted gene therapy for type 1 diabetes mellitus: a systematic review and meta-analysis of rodent studies. Iran J Basic Med Sci 2020; 23:406-415. doi: 10.22038/ijbms.2020.39470.9359

Introduction

Diabetes mellitus (DM) is one of the most important public health challenges worldwide (1, 2), of which type 1 diabetes mellitus (T1DM) (3, 4) is characterized by hyperglycemia caused by autoimmune destruction of pancreatic β -cells, the main site of insulin production and secretion (4). The prevalence of diabetes was estimated to be 422 million in 2014 (1) and expected to reach 522 million in 2030 (5). The total cost of diabetes and pre-diabetes in the US is \$322 billion per annum (6), and health care costs for people with diabetes are 2.3 times higher than those without diabetes (7). Most of the global burden of this disorder is due to morbidity and mortality that arises from complications of the disease (1, 8-13).

The most commonly utilized treatment for T1DM is insulin infusion, which requires close monitoring of blood glucose during insulin therapy, which is then needed daily and reduces patient compliance (14). At the same time, the optimal blood glucose is rarely achieved and patients remain at risk from experiencing regular periods of hypo or hyperglycemia (15, 16). This type of adverse blood glucose places the patient at risk

of hypoglycemic coma or hyperglycemia complications, such as retinopathy, nephropathy, neuropathy, and cardiovascular disease (16, 17). Consequently, a treatment option that is more able to maintain normoglycaemia without adverse complications and greater compliance remains highly desirable (18, 19). Insulin gene therapy is one alternative and represents a novel therapeutic approach to achieving regulated insulin production and delivery (20). Recently, numerous studies have reported the effects of insulin gene therapy on T1DM, which showed some beneficial outcomes in some (21, 22), but not all cases (23). The aim of this paper was to conduct a systematic review and meta-analysis to estimate the effects of insulin gene therapy on T1DM related factors, including bodyweight, intraperitoneal glucose tolerance test (IPGTT), fasting blood glucose, and insulin in diabetic rodents.

Materials and Methods

Search strategy

A comprehensive search was conducted in medical databases including Cochrane reviews, Medline/PubMed, EMBASE, ISI Web of Science, SCOPUS, and

*Corresponding author: Rasoul Salehi. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Gerfa Namayesh Azmayesh (GENAZMA) Science and Research Institute, Isfahan, Iran. Email: r_salehi@med.mui.ac.ir

Table 1. Gene therapy for type 1 diabetes mellitus using non-viral vectors

Reference No.	Country	Study design	Target tissue	Model	Gene delivery method	Route of delivery	Sample size	Result	Adjusted variable								
24	Malaysia	Case control	k-cell & l-cell intestine	Male CD-1 mice	Chitosan GIP/hIns/pBu d	Orally administered the nanoparticles every 2 days	Treat group= 10 Control diabetic= 10 Control normal= 10	Fasting Blood glucose $P<0.05$ mmol/l mean± SD	Age and sex adjusted								
								Days		1	3	5	7	9	11	13	15
								Treat group		25.34± 1.52	24.3± 1.55	21.09± 3.2	18.96± 1.32	18.99±1.3	18.85± 1.09	18.61± 2.17	19.23±0.97
								Control DM		25.27± 0.75	26.19± 0.76	25.26±0.4	26.06± 2	26.51±0.4	25.45± 0.57	26.54±0.6	26.82±0.48
								Control normal		6.36±0.69	6.0± 0.93	5.93±0.9	6.33± 0.95	6.69±1.03	6.11± 0.7	5.99±0.87	5.77±0.98
								Human insulin pmol/l mean± SD									
								Treat group with GIP/Ins		18.217							
								Treat group with GLP-1/Ins/Ins		17.916							
								Control DM		1.048							
								25		China	Case control	k-cell intestine	Male wistar rats	chitosan pCMV/ hIns plasmid	coloclysis	Treat group = 10 Control diabetic= 10	Fasting blood glucose levels mmol/l ($P<0.01$) mean± SD
Days	0	1	2	3	4	5											
Treat group	21.84±1.21	10.2± 0.7	7.1±0.7	6.0± 0.25	5.07± 0.37	8.6± 0.34											
Diabete control	22.7±1.5	23± 1.8	23.5±1.9	22.4±2.3	26±1.5	25.7±2.0											
chitosan	23.5± 1.5	15.7±1.1	14± 1.0	12.3± 1.2	12.5±1.0	13.9±0.8											
Plasma insulin levels pmol/l ($P<0.01$) mean± SD																	
Days	0	1	2	3	4	5											
Treat group	100.49± 10.3	193.76± 8.3	206.2± 9	222.9± 9.7	227.7± 12.7	208.3± 6.2											
Diabete control	100.7± 9.7	100.7± 6.9	97.2± 6.2	92.3± 6.2	93.7±7.6	84.7± 5.55											
chitosan	100.7± 9.7	141.6± 8.3	152.8± 7.6	159.7± 6.9	152.8± 8.3	156.2± 7.6											
26	China	Case control	k-cell intestine	Male wistar rats	chitosan pCMV/ hIns plasmid	coloclysis	Treat group = 10 Control diabetic= 10	Fasting blood glucose levels mmol/l ($P<0.01$) mean± SD	Age and sex adjusted								
								Days		0	1	2	3	4	5	6	7
								Treat group		21.6± 1.0	11.1± 1.0	7± 0.8	6± 0.9	5.07±0.37	11± 0.9	13±0.8	15± 0.8
								Diabete control		21.6± 1.0	22± 1.31	22.5±1.0	25± 1.2	23.2± 1.2	26± 1.0	26.2±1.2	27.1± 1.0
								chitosan		21.6± 1.0	15± 1.1	13±1.0	21.7±0.9	13.5± 1.0	13.8± 0.9	15.2±1.2	15.7± 0.7
								Plasma insulin levels pmol/l ($P<0.01$) mean± SD									
								Days		0	1	2	3	4	5	6	7
								Treat group		98.8± 9.5	194.4±10.5	196.5±10.2	224.3±10.7	227.1±12.5	222.9±7.63	177.7±9	194.4±8.3
								Diabetic control		98.8± 9.5	97.2 ± 7.63	104.1±9	93±7.5	97.9± 8.3	88.2± 8.3	83.3±10	84.7± 8.3
								chitosan		98.8± 9.5	149.3± 8.3	156.2±7.6	152.7±7.8	149.3±8.3	159.7±9.72	156.9±7.6	180.5±9
27	USA	Case control	k-cell intestine	Mice	Linearized GIP/Ins Fragment	Fertilized mouse embryos	Treat group = 10 Control diabetic= 5	Plasma human insulin after glucose challenge mean±SD	Age and sex adjusted								
								Treat group		39 ± 16.9 pmol/l							
								Control DM		0							
27	USA	Case control	k-cell intestine	Mice	Linearized GIP/Ins Fragment	Fertilized mouse embryos	Treat group = 5 Control diabetic= 3	Fasting blood glucose mmol/l mean±SD	Age and sex adjusted								
								Treat group		9.52 ± 1.16							
								Control DM		26 ± 2.63							

Google Scholar up to July 2019 using the following medical subject headings (MeSH) and non-MESH keywords relevant to (“ Gene Therapies “[tiab] OR “ DNA Therapy “[tiab] OR “ Genetic Therapies “[tiab]”) AND (“Genetic Vectors”) AND (“diabetes mellitus”[tiab]”) AND (“insulin”[tiab]”) regardless of language. The reference lists of related articles were then hand-searched for additional relevant studies. Titles/abstracts were screened for relevant studies by two independent investigators.

Study selection

Inclusion and exclusion criteria

Studies were eligible for inclusion in the current analysis if: (i) insulin gene therapy was assessed in animal studies; (ii) their final outcome was diabetes-related factors; and (iii) mean, standard error (SE), or standard deviations (SD) for the mentioned factors were provided. Studies were excluded if they did not include outcome measurements for diabetic control groups or only reported the mean average outcome during the treatment. Two investigators extracted data independently, and any discrepancies were resolved by discussion.

Outcomes

Studies evaluating insulin gene therapy effect on

diabetes-related factors were included in the current study, and the outcomes of interest were IPGTT, fasting blood glucose, insulin, and bodyweight.

Data extraction

The data included the first author, year of publication, country where the study was conducted, sample size, gene delivery route, gene delivery method, target tissue, follow-up duration, main outcome, covariates adjusted for in the analysis and mean and SD or SE. Characteristics of each study on insulin gene therapy by viral and non-viral vector are summarized in Tables 1 and 2, respectively.

Statistical methods

Means after treatment and their SD or SE were collated as the measurable effect of insulin gene therapy on diabetes-related factors. Meta-analysis was performed using the random-effects model and presented as forest plots. Evidence for publication bias was sought by performing Egger’s test in addition to visual inspection of the funnel plots. The percentage of variability across the pooled estimates attributable to heterogeneity beyond chance was estimated with the I^2 index, and the P -value for heterogeneity ($I^2 > 50\%$ was considered as significant heterogeneity). In the case of significant between-study heterogeneity, sensitivity analyses were

Table 2. Gene therapy for type 1 diabetes mellitus using viral vectors

Reference No.	Country	Study design	Target tissue	Model	Gene delivery method	Route of delivery	Sample size	OR,RR	Adjusted variable
28	USA	case control	liver	Male CD-1 mice	GIRE)3BP1-Zxfurwith AAV8 capsids	Portal.vein (in liver)	Treat group= 7 Control diabetic= 5 Control normal= 5	IPGTT: mmol/l mean±SD time 0 30 60 90 120 150 240 300 Treat group 6.27±4.23 12.2±3.65 11.66± 4.39 10.72±4.10 9.44±3.97 8.6± 2.94 6.66±2.65 5±1.32 Control DM 20.1±5.3 25.1±2.24 24.4±1.34 24.3± 2.01 23.5±1.79 22.2±1.12 21.1±2.4 18.3±3.13	Age and sex adjusted
22	Germany	case control	liver	rat	CMV/human furin ins-lentivirus	portal vein	Treat group= 5 Control DM= 6	IPGTT mmol/l mean±SD Time min 0 15 60 120 180 Treat group 4± 1.2 30±2 27±8.94 23±5.59 18±4.47 Control DM 19± 7.35 33± 4 31±7.35 30±4.90 27±4.90	Age and sex adjusted
21	Australia	case control	liver	mice	HMD/INS-FUR lentiviral vector	portal vein	Treat group= 6 Control DM= 6 Control normal= 5	IPGTT mmol/l mean±SD Time min 0 3 5 10 15 30 Treat 7.8±2.20 23.5± 4.16 22.7±6.37 16.1±2.20 11±2.20 7.5±1.71 Control DM 20.4±2.3 30± 7.84 28± 8.33 28.1±7.10 25.8±5.88 23.9±5.63	Age and sex adjusted
29	Australia	case control	liver	rat	HMD/INS-FUR lentiviral vector	(IVC) hepatic artery	Treat group= 5 Control DM= 5 Control normal= 5	IPGTT mmol/l mean±SD Time min 0 20 30 60 90 120 Treat group 7.5± 2.24 16±6.71 16±8.94 14±6.71 11±4.47 8±1.12 Control normal 7± 2.24 14±4.47 15±2.24 12±2.24 10±1.12 7±0.67	Age and sex adjusted
30	Taiwan	case control	liver	Male C57BL/6j mice	rIns I promoter/human furin ins rAAV	into the liver by a single administration	Treat group= 3 Control DM= 3	IPGTT: mmol/l mean±SD Time min 0 30 60 90 120 150 Treat group 7.49± 0.9 16.2 ± 1.4 19.5± 2.7 14.4± 2.2 11.1± 1.1 8.7± 0.4 Control DM 22.4 - 33.3 mmol/l (throughout the experimental period)	Age and sex adjusted
31	Korea	case control	liver	SpragueDawley rats	rAd-SP23137-rINSfur	tail vein	Treat group= 5 Control DM= 7	Blood glucose 24 hr fasting mmol/l mean±SD Treat group 0 24 hr fasting Control DM 7.8± 1.5 5±0.4 Treat group 26.3 ± 2 20±0.6	Age and sex adjusted
28	USA	case control	liver	Male CD-1 mice	GIRE)3BP1-Zxfurwith AAV8 capsids	portal vein (in liver)	Treat group= 7 Control diabetic= 5 Control normal= 5	Blood glucose (P<0.05) (24 hr average cumulative) mean± SD mmol/l Before treat after treat Treat group 6.27± 2.19 2.7 ± 0.79 Control DM 20.2± 2.2 6.77 ± 1.05 Control normal 6.7± 0.16 4± 0.4	Age and sex adjusted
32	USA	case control	liver	rat	retroviral vectors pLX/rINS	portal vein	Treat group= 9 Diabeti control = 8	Fasting blood glucose levels after 24 hr mean±SD mmol/l time 0 24 hr Treat group 11.66±1.7 5± 0.6 Control DM 14.9± 1.8 16.7 ± 3	Age and sex adjusted
33	Germany	case control	liver	rat	HMD/INS-FUR lentiviral vector	portal vein (in liver)	Treat group= 6 Diabeti control = 6	Blood glucose mean after 3 days mean± SD mmol/l before after Treat group 22.3±3.4 15.6 ± 2.1 Control DM 22.3±3.4 22.3 ± 3	Age and sex adjusted
31	Korea	case control	liver	SpragueDawley rats	rAd-SP23137-rINSfur	tail vein	Treat group= 5 Control DM= 7	Blood glucose 24 hr fasting mmol/l mean±SD Treat group 0 24h fasting Control DM 7.8± 1.5 5±0.4 Treat group 26.3 ± 2 20±0.6	Age and sex adjusted
34	Korea	case control	liver	rat	CMV-Ins lentiviral vector	intramuscularly inject	Treat group= 5 Control DM= 5	Fasting blood glucose mean 12 hr fasting (P<0.05) mean± SD mmol/l Treat group 11.1 ± 3 Control DM 19.6± 2.6	Age and sex adjusted
28	USA	case control	liver	Male CD-1 mice	GIRE)3BP1-Zxfurwith AAV8 capsids	portal vein (in liver)	Treat group= 7 Control diabetic= 5 Control normal= 5	Blood glucose average cumulative 57 days (P<0.001) mmol/l mean±SD before after Treat group 20.2± 2.2 5.88 ± 0.6 Control DM 20.2± 2.2 18 ± 1.67 Control normal 6.7± 0.16 6.33 ± 0.0	Age and sex adjusted
29	Australia	case control	Liver	Rat	HMD/INS-FUR lentiviral vector	(IVC) hepatic artery	Treat group= 5 Control DM= 5 Control normal= 5	Blood glucose mmol/l mean±SD time 0 3 days 25 days 50 days 60 days Treat group 7.3± 2.20 7.5 ±3.13 6.3± 4.91 6.5±2.23 6.7 ± 0.67 Control DM 7.4± 2.20 28± 11 28.5 ± 5.36 27±11 27.4 ± 4.0	Age and sex adjusted
21	Australia	case control	liver	mice	HMD/INS-FUR lentiviral vector	portal vein	Treat group= 6 Control DM= 6 Control normal= 5	Blood glucose mmol/l mean± SD Time day 0 5 10 15 Treat 14.1±7.3 7±2.44 8 ±2.44 7±2.55 Control DM 14.2± 7.3 22 ±4.4 26±5.38 28 ±9.79	Age and sex adjusted
22	Germany	case control	liver	rat	CMV/human furin ins-lentivirus	portal vein	Treat group= 5 Control DM= 6	Blood glucose mmol/l Time days 0 5 10 Treat group 25 12.5 12 Control DM 24 25 23	Age and sex adjusted
33	Germany	case control	liver	rat	HMD/INS-FUR lentiviral vector	portal vein (in liver)	Treat group= 6 Diabeti control = 6	Blood glucose mean after 30 days mmol/l mean ± SD Before After Treat group 22.3±3.4 15± 2.8 Control DM 22.3±3.4 21.9 ± 3	Age and sex adjusted
34	Korea	case control	liver	rat	CMV-Ins lentiviral vector	intramuscularly injected	Treat group= 5 Control DM= 5	Blood glucose mmol/l mean± SD Time Before virus inject 10 week after virus inject Treat group 23.4 ± 2.55 17.2 ±3.11 Control DM 23.4 ± 2.55 28	Age and sex adjusted

Continued Table 2

21	Australia	case control	liver	mice	HMD/INS-FUR lentiviral vector	portal vein	Treat group= 6 Control DM= 6 Control normal= 5	Insulin pmol/l after glucose administration mean± SD							Age and sex adjusted		
								Time min	0	3	5	10	15	30	40	40	
								Treat	420± 12.2	1800± 17	1570 ±14.6	870±12.2	810±12.2	730± 12.2	570±12.2	570± 12.2	
								Control DM	Not detected								
								Control norm	420± 11.1	1800± 15.6	1572± 13.4	720±11.1	660± 11.1	662± 8.94	550±11.1	550± 11.1	
30	Taiwan	case control	liver	Male C57BL/6j mice	rIns1 promoter/ human furin ins rAAV	into the liver by a single administration	Treat group= 3 Control DM= 3	Human insulin pmol/l (After glucose administration) mean±SD							Age and sex adjusted		
								Time min	0	30	60	90	120	150			
								Treat group	31.2 ± 3.4	84.72± 12.1	100±5.88	95.14±5.87	77.07 ±12.1	61.8 ± 5.5			
								Control DM	Not detected (0)								
29	Australia	case control	liver	rat	HMD/INS-FUR lentiviral vector	(IVC) hepatic artery	Treat group= 5 Control DM= 5 Control normal= 5	Human Insulin after glucose administration pmol/l							Age and sex adjusted		
								Time min	0	20	30	60	90	120			
								Treat group	50	325	225	75	57	50			
								Control normal	75	350	250	90	85	80			
								Control DM	Not detect								
35	USA	case control	liver	Mouse	CMV/ human ins Lentiviral vector	Intra peritoneal injection	-	Human insulin after 3 month pmol/l							Age and sex adjusted		
								time	0			3 month					
								Treat group	Not detected (0)			88.89					
								Control DM	Not detected (0)			Not detected (0)					
36	Italy	case control	liver	Mouse	L-PKp/ human furin ins (HD-Adv)	portal vein	Treat group= 4 Control DM = 4	Human insulin after 3 week pmol/l							Age and sex adjusted		
								Treat group	896-1333								
								Control DM	not detected								
								Control normal	342.4 ±55								
34	Korea	case control	liver	rat	CMV-Ins lentiviral vector	intramuscularly inject	Treat group= 5 Control DM= 5	Insulin concentration 3 week after virus injection (P=0.077) mean± SD							Age and sex adjusted		
								Treat group	18.75 ± 10 pmol/l								
								Control DM	11.11 ± 7.6 pmol/l								
31	Korea	case control	liver	SpragueDawley rats	rAd-SP23137-rINSfur	tail vein	Treat group= 5 Control DM= 7	Serum rat insulin level pmol/l mean± SD							Age and sex adjusted		
								Time minute	0			30'			120		
								treat	70±1			92±5			75±1		
								Control normal	101± 3			400± 12			223 ± 10		
21	Australia	case control	liver	mice	HMD/INS-FUR lentiviral vector	portal vein	Treat group= 6 Control DM= 6 Control normal= 5	Body weight gram mean± SD							Age and sex adjusted		
								days	0	5	10	15	90	120	150		
								Treat group	22.7±3.9	23±1.8	24.5±5.3	24.8±1.4	27.6±0.7	27.8 ±1.0	28±0.9		
								Control	22.5± 3.86	21.2± 3.8	22± 9.7	21.2±9.2	-	-	-		
28	USA	case control	liver	Male CD-1 mice	GIRE]3BP1-2xflurwith AAV8 capsids	portal vein (in liver)	Treat group= 7 Control diabetic= 5	Body weight gr after 24 hr mean±SD							Age and sex adjusted		
								Time	Before			After 24 hr					
								Treat group	100± 10.5			90±7.9					
								Control DM	100± 6.7			85±4.8					
32	USA	case control	liver	rat	retroviral vectors pLX/rINS	portal vein	Treat group= 16 Diabeti control= 18	Body weight gr after 3 days mean±SD							Age and sex adjusted		
								Time Days	Before			After treat 3 days					
								Treat group	173± 10			171 gr± 10.1					
								Control DM	175± 9			135 gr± 9					
								Control normal	177			180 gr					
29	Australia	case control	liver	rat	HMD/INS-FUR lentiviral vector	(IVC) hepatic artery	Treat group= 5 Control DM= 5 Control normal= 5	Body weight: gram mean± SD							Adjusted for age and sex		
								Time	0	5 days	25 days	50 days	60 days				
								Treat group	300± 11	340±8.94	389±8.9	420±11.18	450±8.94				
								Control DM	292± 13.41	332±10	365±17.88	370±9.39	360±8.94				
34	Korea	case control	liver	rat	CMV-Ins lentiviral vector	intramuscularly injected	Treat group= 5 Control DM= 5	Body weight gram mean±SD							Age and sex adjusted		
								Time	0		5 days		10 week				
								Treat group	121±8.9		115 ± 11 g		135± 33 g				
								Control DM	122± 6.7		116 ± 3.3 g		93± 3.51 g				

performed excluding individual studies to obtain an understanding of the reasons for any differences. Also, where there was a high likelihood of differences beyond chance, subgroup analysis, based on the gene delivery method and follow-up duration, was performed.

Publication bias was assessed statistically by Begg's test. $P < 0.05$ was considered statistically significant. Statistical analyses were conducted using the statistical software package Stata (ver. 11.2).

Results

Search results and characteristics of included studies

The literature search on the subject of gene therapy and diabetes-related factors yielded 654 articles, of which 33 were reviewed as full texts. Of these, 16 studies met the inclusion criteria. The flow diagram summarizes the results of the study selection process for this meta-analysis (Figure 1). Out of 16 studies published 5 (23,27-28, 32, 35) were conducted in the USA, and 2 (22, 23), 2 (21, 29), 2 (31, 34), 2 (25, 26), 1 (36), 1 (30), 1 (24) studies were published respectively

in Germany, Australia, Korea, China, Italy, Taiwan, and Malaysia. Six (21, 22, 28-31), 13 (21-29, 31-34), 5 (21, 28, 29, 32, 34), and 11 (21, 23-26, 29-31, 34-36) studies assessed the effects of insulin gene therapy on IPGGT, FBS, bodyweight, and blood insulin, respectively. The sample size ranged from 3 animals to 18 with follow-up ranging from 2 min to 3 months. Target tissue was based on the liver in all of the viral vector studies and K-cell in non-viral vector studies. The gene delivery method was a viral vector in 11 studies (21, 22, 28, 32, 33, 36), which used the portal vein as the route of delivery. Others (29-31, 34, 35) used the hepatic artery and tail vein. Four studies used a non-viral vector as a gene delivery method, of which 2 (25, 26) used colocalysis as the route of delivery. The remaining used an oral route (24) or the pronuclei of fertilized mouse embryos (27).

Findings from the systematic review:

Some studies that were initially included were subsequently excluded and were reported in a systematic study.




Figure 1. The flow diagram of study selection

Hsu *et al.* reported effect of insulin gene therapy on IPGTT; the IPGTT difference before glucose administration and 150 min after glucose administration in treat group was 1.21 mmol/l but in control diabetic group it was 10.9 mmol/l throughout the experimental period. Therefore, glucose was significantly decreased in the treat group. Similarly, the insulin level in the treat group was significantly increased (30.6 ± 2.1 pmol/l) compared to the control group (30).

Another study showed that insulin gene therapy affected IPGTT and that the difference in blood glucose before and after insulin gene therapy in the treat group was 9.54 ± 1.2 mmol/l (15.04 ± 1.6 mmol/l to 5.49 ± 0.4 mmol/l), whereas in the normal control group it was 5.55 ± 0.6 mmol/l throughout the experimental period. Therefore, glucose was significantly decreased without any apparent significant differences in insulin (23). However, Rasouli *et al.* reported insulin gene therapy by GIP/Ins/pBud increased insulin in comparison to controls (1.048 pmol/l) (24). Similarly, Cheung used GIP/Ins fragments and injected them into pro-nuclei of fertilized mouse embryos. In the transgenic mice mean blood glucose and human insulin was 9.52 ± 1.16 mmol/l and 39 ± 16.9 pmol/l, respectively, which showed decreased blood glucose and raised human insulin (27).

Findings from the meta-analysis on insulin gene therapy and IPGGT

Gene therapy by viral vector

Five studies were identified (21, 22, 28-30), including 28 datasets that met the inclusion criteria based on their mean IPGGT after insulin gene therapy by viral vector that was reduced on average by -12.69 mmol/l ($P < 0.001$) (Figure 2). Publication bias was observed ($P = 0.007$) after using the trim-and-fill method to adjust for funnel plot asymmetry, although these results




Figure 2. Mean of IPGGT after insulin gene therapy by viral vectors

were unchanged. Between-study heterogeneity was also found ($I^2 = 98.1$, $P < 0.001$). The sensitivity analysis revealed that the exclusion of any single study did not alter the overall effect. For each study, assessment follow-up duration after treatment was classified as ≤ 30 min (ID=1), ≥ 60 and ≤ 90 min (ID=2), and ≥ 120 and ≤ 300 min (ID=3). Such subgroup analysis (Figure 3) showed no heterogeneity between studies, although the summary mean for IPGGT after ≥ 120 and ≤ 300 min was lower (-15.46 mmol/l, $P < 0.001$) than achieved at ≤ 30 min (-11.12 mmol/l, $P = 0.001$) and ≥ 60 and ≤ 90 (-11.25 mmol/l, $P = 0.006$). The gene delivery method (AAV) (ID=1), r Adeno (ID=2) and lentiviral (ID=3), modified the IPGGT response that was greatest with the r Adeno method, (-25.87 mmol/l, $P < 0.001$) compared to AAV (-13.60 mmol/l, $P < 0.001$) and the lentivirus (-5.17




Figure 3. Subgroup analysis by follow-up duration for the mean of IPGGT after insulin gene therapy by viral vectors




Figure 4. Subgroup analysis by gene delivery methods for the mean of IPGGT after insulin gene therapy by viral vectors

mmol/l, $P < 0.009$) (Figure 4).

Findings from the meta-analysis on insulin gene therapy and FBS:

Gene therapy by viral vector

Eight studies with 15 datasets describing the effects of insulin gene therapy by viral vectors gave a mean reduction in FBS (-13.51 mmol/l) (21, 22, 28, 29, 31-34) (Figure 5). No evidence of publication bias was found ($P = 0.86$). The I^2 value indicates 96.3% of the variability was accounted for across the pooled estimates. Sensitivity analysis showed the exclusion of each study from the analysis did not change the overall effect. Subgroup analysis by follow-up duration confirmed a prominent effect ($P < 0.001$) of insulin gene therapy on FBS at ≤ 5 days (ID=1), ≥ 10 and ≤ 30 days (ID=2), and ≥ 50 and ≤ 70 days (ID=3) (Figure 6). Insufficient studies in AAV, retroviral, and viral subgroups meant analysis according to gene delivery method was not possible.




Figure 5. Mean of FBS after insulin gene therapy by viral vectors




Figure 6. Subgroup analysis by follow-up duration for the mean of FBS after insulin gene therapy by viral vectors

Gene therapy by non-viral vector

Meta-analysis from three studies including 20 datasets that used non-viral vectors (24-26) also showed reduced FBS (-29.95 mmol/l, $P < 0.001$) (Figure 7). Egger's test was significant ($P = 0.001$), but applying trim and fill had no effect on the outcome, as there was between-study heterogeneity ($I^2 = 98.8$, % $P = P < 0.001$). The exclusion of each study from the meta-analysis did not impact the overall sensitivity analysis. According to follow-up duration, studies were categorized into ≤ 1 day (ID=1), ≥ 7 , and ≤ 15 days (ID=2) (Figure 8), and the magnitude of effect increase with time of follow up, i.e., FBS at ≤ 1 days, -16.08 g ($P < 0.001$) compared with ≥ 7 and ≤ 15 days, -112.09 g ($P < 0.001$).

Findings from the meta-analysis on insulin gene therapy and blood insulin

Gene therapy by viral vector

Meta-analysis of 6 studies (21, 31, 32, 34-36) with 20 datasets describing the effects of insulin gene therapy with lentiviral carriers on blood insulin showed a mean




Figure 7. Mean of FBS after insulin gene therapy by non-viral vectors




Figure 8. Subgroup analysis by follow-up duration for the mean of FBS after insulin gene therapy by non-viral vectors

increase of 398.3 pmol/l ($P < 0.001$) (Figure 9). There was no publication bias ($P = 0.06$) and overall heterogeneity ($I^2 = 100\%$), as well as between-study heterogeneity for the duration of measurement, i.e., ≤ 10 min ($ID = 1$), ≥ 15 and ≤ 30 min ($ID = 2$), ≥ 40 and ≤ 60 min ($ID = 3$), ≥ 90 and ≤ 150 min ($ID = 4$), ≥ 21 , and ≤ 90 days ($ID = 5$) (Figure 10).

Gene therapy by non-viral vector

Random-effects meta-analysis confirmed the effects of insulin gene therapy with non-viral carriers on raised blood insulin by 114.9 pmol/l ($P < 0.001$) (Figure 11). There was no evidence of publication bias ($P = 0.70$), and heterogeneity between studies was high ($I^2 = 94.9\%$),




Figure 9. Mean of insulin level after insulin gene therapy by viral vectors




Figure 10. Subgroup analysis by follow-up duration for the mean of insulin level after insulin gene therapy by viral vectors

which was unaffected by one study or follow-up duration (Figure 12).

Findings from the meta-analysis on insulin gene therapy and bodyweight

Gene therapy by viral vector

Gene therapy by viral vectors increased bodyweight (Figure 13) in 5 studies (21, 24, 25, 29, 31) with 11 datasets, which increased by 24.2 g ($P < 0.001$). There was no evidence of publication bias ($P = 0.45$), and between-study heterogeneity was apparent ($I^2 = 96.4\%$,




Figure 11. Mean of insulin level after insulin gene therapy by non-viral vectors

$P < 0.001$), with no single study influencing the final effect. Subgroup analysis by follow-up duration showed an increased response with time, i.e., ≤ 5 days (ID=1), 13.3 g, ($P < 0.01$); between ≥ 50 and ≤ 70 days (ID=3), 62.1 g, ($P < 0.001$); but no effect during ≥ 10 and ≤ 25 days (ID=2) (7.09 g $P = 0.14$) (Figure 14). Due to insufficient studies in the AAV and retroviral, subgroup analysis according to gene delivery methods was not performed.

Discussion

Reducing blood glucose in T1DM is necessary to avoid side effects such as neuropathy, glaucoma, nephropathy, and cardiomyopathy (37-40), for which the most popular treatment is insulin injection, although this is not very practical. It can also cause hyperinsulinemia, which is a risk factor for progressive insulin resistance and cardiovascular damage (41, 42). Therefore insulin gene therapy is currently a focus of future T1DM treatment, with the restoration of a dynamic and more precise method of insulin production (43). The different approaches that can be used to more effectively maintain euglycemia are promoting the survival and proliferation




Figure 12. Subgroup analysis by follow-up duration for the mean of insulin level after insulin gene therapy by non-viral vectors




Figure 13. Mean of bodyweight after insulin gene therapy by viral vectors

of islets β cells, preventing their destruction by the immune system, and the employment of non-islets β cells such as hepatocytes, myocytes, fibroblasts, and intestinal and gastric epithelial cells to regulate insulin release (20). Also, gene targeting in T1DM can be achieved using viral or non-viral vectors (43, 44), for which the former is more effective (45). We have performed the first systematic review and meta-analysis to investigate the efficiency of insulin gene therapy for IPGTT, FBS, insulin, and bodyweight.

IPGTT studies on streptozocin (STZ)-induced diabetic mice treated with the insulin gene, delivered intrapancreatically by recombinant Ad (rAD) vector, corrected hyperglycemia and glucose tolerance (31). This response was, however, transient and typically persisted for only 1-3 weeks (20). Studies on STZ-induced diabetic rodents treated with the insulin gene showed that all gene therapies decreased blood glucose and increased insulin. Because lentiviruses and retroviruses are integrative vectors, they can elicit long-term benefits, as shown in rats (29) and mice (21). In both studies, an HMD/INS-FUR construct using INS-




Figure 14. Subgroup analysis by follow-up duration for the mean of weight after insulin gene therapy by viral vectors

FUR was cloned into the site of LV HIV/MSCV (HMD) and injected into the portal vein by intervallic fusion to be delivered into the liver. In STZ-induced diabetic rats, blood glucose was returned to normal for at least 500 days without any adverse response.

One of the other factors associated with insulin gene therapy for T1DM is increased bodyweight, as diabetes improves, as confirmed by our meta-analysis. We also showed significant effects on FBS and blood insulin by non-viral vectors. Until recently, a major limitation of viral insulin therapy has been the lack of meal-dependency on insulin secretion in these surrogate cells. K-cells are native endocrine cells that are glucose-responsive native endocrine cells, located primarily in the stomach, duodenum, jejunum, and gut hormone GIP (46), which normally potentiates postprandial insulin release (27). It has therefore been proposed that K-cells may be suitable targets for T1DM insulin gene therapy (47), although they have a short lifespan of 3–5 days, which necessitates frequent and repeated gene administration. Taking all these studies together, we observed substantial heterogeneity due to animal type, sample volume, the method of determining T1DM and the gene delivery method. Therefore, the random effect model was used to reduce these contrasting effects but could not find the sources of the heterogeneity, which suggests that the efficacy of insulin gene therapy is variable. In spite of these limitations, including publication bias, our study had several strengths, being the first meta-analysis focused on the effects of insulin gene therapy on T1DM related factors.

Conclusion

The meta-analysis findings showed a significant effect for insulin gene therapy and T1DM related factors, including IPGTT, fasting blood glucose, insulin, and bodyweight in diabetic rodents.

Acknowledgment

Rasoul Salehi wishes to express his gratitude to the Ministry of Health and Medical Education of Iran as well as the Vice-Chancellor for Research, Isfahan University of Medical Sciences, Isfahan Iran, for awarding the Avicenna Research Grant to him.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

1. World Health Organization. Global report on diabetes: World Health Organization; 2016.
2. Beladi-Mousavi SS, Bashardoust B, Nasri H, Ahmadi A, Tolou-Ghamari Z, Hajian S, et al. The theme of the world diabetes day 2014; healthy living and diabetes; a nephrology viewpoint. *J Nephrothermol*. 2014;3:43.
3. Katsarou A, Gudbjörnsdóttir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. *Nat Rev Dis Primers*. 2017;3:1-17.
4. Yoon J-W, Jun H-S. Autoimmune destruction of pancreatic β cells. *Am. J. Ther*. 2005;12:580-91.
5. Guo S. Decoding insulin resistance and metabolic syndrome for promising therapeutic intervention. *J Endocrinol* 2014;220:E1-3.
6. Nathan DM. Diabetes: advances in diagnosis and treatment. *Jama* 2015;314:1052-62.
7. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2012. Available in *Diabetes Care*. 2013;36:1033-1046.
8. Miraghajani MS, Esmailzadeh A, Najafabadi MM, Mirlohi M, Azadbakht L. Soy milk consumption, inflammation, coagulation, and oxidative stress among type 2 diabetic patients with nephropathy. *Diabetes Care*. 2012;35:1981-1985.
9. Miraghajani MS, Najafabadi MM, Surkan PJ, Esmailzadeh A, Mirlohi M, Azadbakht L. Soy milk consumption and blood pressure among type 2 diabetic patients with nephropathy. *J Ren Nutr*. 2013;23:277-282.
10. Miraghajani M, Zaghian N, Mirlohi M, Feizi A, Ghasvand R. The Impact of Probiotic Soy Milk Consumption on Oxidative Stress Among Type 2 Diabetic Kidney Disease Patients: A Randomized Controlled Clinical Trial. *J Ren Nutr* 2017;27:317-324.
11. Miraghajani M, Zaghian N, Mirlohi M, Ghasvand R. Probiotic Soy Milk Consumption and Renal Function Among Type 2 Diabetic Patients with Nephropathy: a Randomized Controlled Clinical Trial. *Probiotics Antimicrob Proteins*. 2017:1-9.
12. Kareem N, Nazar CMJ, Mahmud SN, Ahmed A, Akhtar MH. Diabetes services and care provision. *J Nephrothermol*. 2017;6:17.
13. Motedayen M, Sarokhani D, Meysami A, Jouybari L, Sanagoo A, Hasanpour Dehkordi A. The prevalence of hypertension in diabetic patients in Iran; a systematic review and meta-analysis. *J Nephrothermol*. 2018;7:137-44.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993;347:977-986.
15. Nasri H. Ameliorative impact of mycophenolate mofetil on diabetic kidney disease; a review on current knowledge. *Immunopathol Persa*. 2018;4:e19.
16. Mahmoodnia L, Aghadavod E, Beigrezaei S, Rafieian-Kopaei M. An update on diabetic kidney disease, oxidative stress and antioxidant agents. *J Renal Inj Prev*. 2017;6:153.
17. Fowler MJ. Microvascular and Macrovascular Complications of Diabetes. *Clinical Diabetes*. 2008;26: 77-82.
18. Xu R, Li H, Lai-yin T, Hsiang-fu K, Lu H, Lam K. Diabetes gene therapy: potential and challenges. *Curr Gene Ther*. 2003;3:65-82.
19. Hosseini SM, Amini M, Roosta S, Beigrezaei S. Trends of serum creatinine among patients with type 2 diabetes in Isfahan endocrine and metabolism research center; a longitudinal study. *J Prev Epidemiol*. 2016;2: e01.
20. Shrestha N, Araújo F, Sarmiento B, Hirvonen J, Santos HA. Gene-based therapy for Type 1 diabetes mellitus: viral and nonviral vectors. *Diabetes Management*. 2014;4:367.
21. Ren B, O'Brien BA, Byrne MR, Ch'ng E, Gatt PN, Swan MA, et al. Long-term reversal of diabetes in non-obese diabetic mice by liver-directed gene therapy. *J Gene Med*. 2013;15:28-41.
22. Elsner M, Terbish T, Jörns A, Naujok O, Wedekind D, Hedrich H-J, et al. Reversal of diabetes through gene therapy of diabetic rats by hepatic insulin expression via lentiviral transduction. *Mol ther*. 2012;20:918-926.
23. Olson DE, Paveglio SA, Huey PU, Porter MH, Thulé PM. Glucose-responsive hepatic insulin gene therapy of spontaneously diabetic BB/Wor rats. *Hum gene ther*. 2003;14:1401-1413.
24. Rasouli M NAZ, R Omar A, Ahmad Z. Insulin secreted from genetically engineered intestinal cells reduces blood glucose levels in diabetic mice. *Curr gene ther*. 2013;13:229-239
25. Niu L, Dai Z. Expression of human insulin gene wrapped with chitosan nanoparticles in NIH3T3 cells and diabetic rats. *Acta Pharmacol Sin*. 2008;29:1342-1349
26. Niu L, Xu Y-C, Dai Z, Tang H-Q. Gene therapy for type 1

- diabetes mellitus in rats by gastrointestinal administration of chitosan nanoparticles containing human insulin gene. *World j gastroenterol.* 2008;14:4209.
27. Cheung AT, Dayanandan B, Lewis JT, Korbitt GS, Rajotte RV, Bryer-Ash M, et al. Glucose-dependent insulin release from genetically engineered K cells. *Science.* 2000;290:1959-1962.
28. Thulé PM, Campbell AG, Jia D, Lin Y, You S, Paveglio S, et al. Long term glycemic control with hepatic insulin gene therapy in streptozotocin-diabetic mice. *J gene med.* 2015;17:141-152.
29. Ren B, O'Brien B, Swan M, Koina M, Nassif N, Wei M, et al. Long-term correction of diabetes in rats after lentiviral hepatic insulin gene therapy. *Diabetologia.* 2007;50:1910-1920.
30. Hsu PY-J, Kotin RM, Yang Y-W. Glucose-and metabolically regulated hepatic insulin gene therapy for diabetes. *Pharm res.* 2008;25:1460-1468.
31. Han J, McLane B, Kim E-H, Yoon J-W, Jun H-S. Remission of diabetes by insulin gene therapy using a hepatocyte-specific and glucose-responsive synthetic promoter. *Mol ther.* 2011;19:470-478.
32. Kolodka TM, Finegold M, Moss L, Woo S. Gene therapy for diabetes mellitus in rats by hepatic expression of insulin. *Proc Nati Acad Sci.* 1995;92:3293-3297.
33. Elsner M, Jörns A, Lenzen S. Diabetes therapy by lentiviral hepatic insulin gene expression without transformation of liver. *Diabetologia.* 2008;51:694-695.
34. Oh TK, Li MZ, Kim ST. Gene therapy for diabetes mellitus in rats by intramuscular injection of lentivirus containing insulin gene. *Diabetes res clin pract.* 2006;71:233-240.
35. Oded Singer FG, Jerry Olefsky, Inder M. Verma. Gene Therapy for Diabetes Using Lentiviral Vectors. *Mol Ther* 2002;5:S340.
36. Corbella P, Perani L, Mingozi F, Recchia A, Mavilio F, Roncarolo M, et al. Insulin-gene therapy of diabetes in mice by glucose-regulated helper-dependent adenoviral vectors. *Mol ther.* 2003;7:79-80.
37. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. *Lancet.* 2001;358:221-229.
38. Aghadavoud E, Nasri H, Amiri M. Molecular signaling pathways of diabetic kidney disease; new concepts. *J Prev Epidemiol.* 2017;2:e03
39. Ghaderian SB, Beladi-Mousavi SS. The role of diabetes mellitus and hypertension in chronic kidney disease. *J renal inj prev.* 2014;3:109-110.
40. Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. *J nephropharmacol.* 2016;5:49-56.
41. Stern MP, Haffner SM. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. *Arteriosclerosis.* 1986;6:123-30.
42. Velayuthan MR, Elumalai R, Periyasamy S, Lakkakula BV. Insulin receptor gene polymorphisms modify the progression of kidney failure in diabetic nephropathy patients. *J Prev Epidemiol.* 2017;2:e06.
43. Palizban A, Salehi R, Nori N, Galehdari H. *In vivo* transfection rat small intestine K-cell with pGIP/Ins plasmid by DOTAP liposome. *J drug target.* 2007;15:351-357.
44. Momenzadeh S, Sadeghi A, Vatandoust N, Salehi R. Evaluation of *In Vivo* Transfection Efficiency of Eudragit Coated Nano-particles of Chitosan-DNA: A pH-sensitive System Prepared for Oral DNA Delivery. *Iran Red Crescent Med J.* 2015;17: e16761.
45. Handorf AM, Sollinger HW, Alam T. Insulin gene therapy for type 1 diabetes mellitus. *Exp clin transplant.* 2015;13:37-45.
46. Yeung C-M, Wong CK, Chung SK, Chung SS, Chow BK. Glucose-dependent insulinotropic polypeptide gene expression in the stomach: revealed by a transgenic mouse study, in situ hybridization and immunohistochemical staining. *Mol cell endocrinol.* 1999;154:161-170.
47. Cho YM, Kieffer TJ. 4 K-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease. *Vitam horm.* 2010;84:111.